AU Patent

AU2016333334B2 — 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer

Assigned to Deutsches Krebsforschungszentrum DKFZ · Expires 2019-07-25 · 7y expired

What this patent protects

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.

USPTO Abstract

The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: AU2016333334B2
Jurisdiction: AU
Classification: —
Expires: 2019-07-25
Drug substance claim: No
Drug product claim: No
Assignee: Deutsches Krebsforschungszentrum DKFZ
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.